The transaction includes $70m in cash and a $20m retained equity position for Nektar in a new Ampersand portfolio company.

After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...

Nektar Therapeutics (Nasdaq: NKTR), a global biotechnology company focused on the discovery and development of novel therapies to treat autoimmune disorders, today announced that it has entered into a ...

Therapeutics announced that it has entered into a definitive agreement to sell its Huntsville, Alabama manufacturing facility and ...

(RTTNews) - Nektar Therapeutics (NKTR), Monday announced a decision to sell its Alabama-based commercial-scale manufacturing facility and PEGylation reagent supply business to Ampersand Capital ...

BOSTON, Oct. 31, 2024 /PRNewswire/ -- For the third consecutive year, Ampersand Capital Partners has been named to Inc.'s 2024 Founder-Friendly Investors list, which honors the private equity and ...

Ampersand Biosciences and Trudeau Institute have been awarded more than $1 million to study infectious diseases.

Ampersand Advocates has announced the launch of an innovative digital engagement channel specifically designed for Personal ...

Ampersand Capital Partners, founded in 1988, is a middle-market private equity firm with $3 billion of assets under management, dedicated to growth-oriented investments in the healthcare sector.

Ampersand reaches 1150 bikes on the roads of Nairobi Expansion underscores company's commitment to cutting carbon emissions and driving clean economic prosperity across Africa Nairobi – Ampersand, ...